Clinical Trials Logo

Insulin Resistance clinical trials

View clinical trials related to Insulin Resistance.

Filter by:

NCT ID: NCT01631370 Completed - Insulin Resistance Clinical Trials

The Effects of Renal Denervation on Insulin Sensitivity

Start date: June 2012
Phase: N/A
Study type: Interventional

Renal sympathetic nerves contribute to development of hypertension. Sympathetic overactivity also induces insulin resistance and it could therefore be assumed that a renal denervation might improve insulin sensitivity. Studies have shown that glucose metabolism is improved in patients with treatment resistant essential hypertension both 1 and 3 months after renal denervation compared to a control group with treatment resistant essential hypertension. Fasting glucose, insulin and C-peptide decreased significantly as did insulin resistance assessed by HOMA-IR. The investigators wish to investigate the effect of renal denervation on insulin sensitivity using the gold standard - the hyperinsulinemic euglycemic clamp and to investigate the degree of insulin resistance in muscle, liver and adipose tissue.

NCT ID: NCT01623934 Active, not recruiting - Insulin Resistance Clinical Trials

Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development

GEN3G
Start date: January 2010
Phase: N/A
Study type: Observational

This study includes 2 phases. During phase 1, pregnant women are followed over the course of pregnancy. The phase 2 is a follow-up of the mother-child dyad at 3 and 5 year after delivery. The purpose of this phase 1 is to : - assess the contribution and interactions of adipokines in the development of insulin resistance during pregnancy and gestational diabetes; - assess levels of maternal adipokines as determinants of development and fetal growth; - determine the genetic variations that influence levels of adipokines and glucose regulation during pregnancy and in newborns. The purpose of this phase 2 is to: - identify DNA methylation variations at birth that are predictive of childhood overweight/obesity. - identify maternal characteristics associated with DNA methylation variations predictive of childhood overweight/obesity. - establish whether the loci predictive of childhood overweight/obesity at birth are still differentially methylated at 5 years of age (samples collected at 5 years of age). - identify DNA methylation variations at birth that are predictive of childhood neurodevelopment problems at 3 and 5 years of age.

NCT ID: NCT01621516 Completed - Diabetes Clinical Trials

Measurement of the Pancreas Function in Patients With More Than One Pancreas After Liver and Small Bowel Transplantation

Start date: June 2012
Phase: N/A
Study type: Observational

Under chronic immunosuppressive and corticosteroid therapy, transplant patients have a tendency to develop in the long-term diabetes. Patients who have received extra pancreatic tissue with their liver and small bowel transplantation have not yet developed insulin resistance or diabetes mellitus. We would like to investigate to which level insulin secretory capacity the extra pancreas together with the native pancreas has in these transplant patients using the hyperglycemic clamp. These data will be compared with the data obtained from healthy controls.

NCT ID: NCT01620684 Recruiting - Obesity Clinical Trials

Cortisol and Nutritional Sympathetic Responsiveness

Start date: February 2013
Phase: Phase 4
Study type: Interventional

This project will examine whether short-term (over a 12-hour period) pharmacological lowering of the stress hormone 'cortisol' improves the nervous system response to food intake in overweight or obese individuals who have metabolic syndrome. The investigators know from our previous research that overweight/obese persons who are insulin resistant, have a blunted sympathetic nervous response to carbohydrate ingestion. This means that they are less able to dissipate energy from caloric intake, which would favour the maintenance of the obese state. Cortisol adversely impacts on insulin action and transport into the brain and cortisol levels are often elevated in persons with central (abdominal) obesity. A randomized, double-blind, placebo controlled, cross-over design will be used to compare the effects of overnight treatment with metyrapone (15 mg/kg at midnight and 15 mg/kg at 6 am) versus placebo on sympathetic nervous system activity in response to a standard 75-g oral sugar (glucose) tolerance test. A 2 week washout will separate treatments. Metyrapone is a drug that reversibly inhibits the enzyme 11beta-hydroxylase, and therefore the production of cortisol. It is used clinically to test the activity of the adrenal gland (the key site of cortisol production) and the pituitary gland. The investigators anticipate that at the dosage used, it will lower blood cortisol concentration by 44 to 64% during the experimental morning. The study protocol comprises two screening visits and two experimental mornings. Key procedures will include: - Assessment of insulin action (sensitivity) using the gold standard 'clamp' method. - Measurement of sympathetic nervous system activity by both biochemical methods (isotope dilution which provides a measure of the apparent rate of release of 'noradrenaline'-the key neurotransmitter in the sympathetic nervous system) and direct intra-neuronal nerve recordings from the peroneal nerve in the lower leg. - Indirect calorimetry to assess resting metabolic rate and the response to sugar ingestion. - DEXA scan to quantify fat and lean mass. - Assessment of arterial elasticity and calf blood flow by non-invasive methods. - A standard 75g oral sugar tolerance test. The results will provide important new information regarding the role of cortisol on nervous system function in overweight/obese individuals.

NCT ID: NCT01620125 Completed - Type 2 Diabetes Clinical Trials

Metabolic Control Before and After Supplementation With Lactobacillus Reuteri DSM 17938 in Type 2 Diabetes Patients

Start date: May 2012
Phase: Early Phase 1
Study type: Interventional

Recent data suggest that the trillions of bacteria in the investigators gastrointestinal tracts (gut microbiota) can function as an environmental factor that modulates the amount of body fat. Obese individuals have an altered gut microbiota and germ-free mice are resistant to developing diet-induced obesity and have lower fasting insulin and glucose and improved glucose tolerance. Administration of the probiotic bacterium Lactobacillus strain in fermented milk for 12 weeks reduced adiposity and body weight in obese adults, possibly by reducing lipid absorption and inflammatory status. However, there are no studies to the investigators knowledge that address whether probiotic supplementation improves glucose metabolism in type 2 diabetes patients.

NCT ID: NCT01617304 Completed - Obesity Clinical Trials

Effects of Food Cooking on Diabetes-2 Risk Factors

Age-2
Start date: December 2011
Phase: N/A
Study type: Interventional

The aim of the project is to investigate the effects of advanced glycation end products (AGEs) formed in food during the cooking process as well as AGEs formed naturally in the human body, on insulin sensitivity and risk factors for type 2 diabetes. The hypothesis is that i) food content of AGEs is lower using boiling and steaming cooking methods and that ii) AGEs formation in the body is lower at low dietary intake of certain sugar forms.

NCT ID: NCT01616134 Completed - Obesity Clinical Trials

Effect of Korean Red Ginseng on Insulin Sensitivity in Non Diabetic Overweight Korean Adults

KRGIS
Start date: August 2010
Phase: N/A
Study type: Interventional

Korean red ginseng (KRG) is popular worldwide since it is believed to contain ingredients with a variety of health enhancement effects. Several in vitro studies and animal studies showed that ginseng has anti-obesity, anti-diabetic and anti-metabolic disease effects. Several studies involving type 2 diabetes mellitus (T2DM) patients reported that administration of KRG for 12 weeks resulted in positive effects on the maintenance of sugar control effect and improvement of insulin resistance Although there is evidence to suggest that KRG could efficacious reduction in postprandial glycemia, the benefits of long-term KRG in healthy individuals on insulin sensitivity has not yet been established. Therefore, we investigated whether KRG affected insulin sensitivity in healthy overweight or obese Korean subjects without overt diabetes.

NCT ID: NCT01610154 Recruiting - Insulin Resistance Clinical Trials

Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics― the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics

Start date: May 2012
Phase: N/A
Study type: Observational

1. The purpose of this study is to determine whether Sitagliptin therapy suppress glucagon release and improve glucose control in Chinese type 2 diabetic. 2. There are different effects of Sitagliptin therapy on blood glucose regulation, pancreatic alpha & beta cell function are different in lean (BMI<25) and overweight (BMI>25) Chinese type 2 diabetics. 3. The purpose of this study is to determine whether glucagon release may contribute over 30% to the hyperglycemia in Chinese type 2 diabetics.

NCT ID: NCT01605071 Completed - Insulin Resistance Clinical Trials

Timing Estrogen After MenoPaUSe

TEMPUS
Start date: September 2011
Phase: N/A
Study type: Interventional

The aim of the current study is to test whether the effect of estrogen on insulin metabolism depends on the timing of treatment relative to when a woman went through menopause. The investigators hypothesize that estrogen will improve insulin sensitivity in early postmenopausal women, but decrease insulin sensitivity in late postmenopausal women.

NCT ID: NCT01593397 Completed - Obesity Clinical Trials

Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity

Start date: November 2011
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to determine the influence of insulin resistance on drug metabolism and response in obese subjects. The investigators hypothesize that expression of adiponectin (a hormone secreted by fat tissue), and specific variants in the adiponectin gene can predict the insulin resistance and drug response among obese subjects.